Biotech Values

[mcbio]

Not really, IMO. Despite the impressive phase-2 data (#msg-38279562), Bavarian Nordic has been shopping the drug without apparent success (#msg-56482746).

Doing a bit more DD on Bavarian Nordic. They claim in http://www.bavarian-nordic.com/investor/announcements/2011-03.aspx that their decision to move forward into Phase 3 trials with ProstVac on their own was not due to lack of interest from potential partners but due to their unhappiness with proposed deal terms. While I realize there are still concerns given those kind of comments, assuming we can take the PR at face value, perhaps this is an incremental positive for Bavarian Nordic in that there is at least apparently interest in ProstVac from potential partners. Just sounds like they may have to reduce their expectations to partner before P3 results or hope P3 results are strong to justify their expectations.